Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 21.23
-0.80 (-3.63%)
At close: Sep 10, 2026
Enwei Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 823.97 | 896.64 | 808.19 | 781.2 | 687.5 | 675.79 |
Other Revenue | 2.16 | 4.14 | 3.94 | 3.99 | 4.07 | 3.91 |
| 826.13 | 900.77 | 812.13 | 785.19 | 691.57 | 679.7 | |
Revenue Growth | -5.39% | 10.91% | 3.43% | 13.54% | 1.75% | 7.18% |
Cost of Revenue | 409.13 | 453.37 | 404.17 | 384.36 | 346.2 | 298.67 |
Gross Profit | 417 | 447.41 | 407.96 | 400.83 | 345.37 | 381.03 |
Selling, General & Admin | 372.85 | 370.52 | 342.52 | 292.84 | 258.17 | 264.71 |
Research & Development | 5.36 | 5.52 | 9.07 | 16.82 | 7.52 | 4.32 |
Other Operating Expenses | 9.57 | 11.27 | 12.56 | 10.89 | 9.89 | 11.64 |
Operating Expenses | 387.98 | 388.4 | 365.98 | 320.45 | 277.06 | 281.34 |
Operating Income | 29.02 | 59 | 41.98 | 80.38 | 68.31 | 99.69 |
Interest Expense | -0.92 | -2.56 | -2.43 | - | - | - |
Interest & Investment Income | 6.01 | 8.34 | 7.59 | 10.3 | 1.99 | 0.52 |
Other Non Operating Income (Expenses) | 2.36 | -0.99 | -0.08 | -0.66 | -0.27 | -0.88 |
EBT Excluding Unusual Items | 36.47 | 63.79 | 47.07 | 90.03 | 70.03 | 99.33 |
Gain (Loss) on Sale of Investments | -4.32 | -4.32 | - | - | - | -0.44 |
Gain (Loss) on Sale of Assets | -0 | -0.14 | -0.26 | -0.04 | - | - |
Asset Writedown | -0.1 | -0.2 | -0.05 | - | - | -0.01 |
Other Unusual Items | 4.34 | 5.03 | -0.06 | 11.33 | 11.83 | 20.25 |
Pretax Income | 36.39 | 64.16 | 46.68 | 101.31 | 81.86 | 119.13 |
Income Tax Expense | 6.77 | 12.22 | 9.19 | 15 | 14.06 | 17.39 |
Earnings From Continuing Operations | 29.62 | 51.94 | 37.5 | 86.31 | 67.8 | 101.73 |
Net Income | 29.62 | 51.94 | 37.5 | 86.31 | 67.8 | 101.73 |
Net Income to Common | 29.62 | 51.94 | 37.5 | 86.31 | 67.8 | 101.73 |
Net Income Growth | -48.84% | 38.53% | -56.56% | 27.30% | -33.36% | 3.03% |
Shares Outstanding (Basic) | 104 | 103 | 101 | 103 | 84 | 78 |
Shares Outstanding (Diluted) | 105 | 103 | 101 | 103 | 84 | 78 |
Shares Change | 4.65% | 2.06% | -1.82% | 21.93% | 8.34% | 6.51% |
EPS (Basic) | 0.28 | 0.50 | 0.37 | 0.84 | 0.80 | 1.31 |
EPS (Diluted) | 0.28 | 0.50 | 0.37 | 0.84 | 0.80 | 1.31 |
EPS Growth | -51.12% | 35.73% | -55.75% | 4.40% | -38.49% | -3.27% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 50.66 | 53.21 | 28.69 | -50.04 | 38.8 | 49.36 |
Free Cash Flow Per Share | 0.48 | 0.52 | 0.28 | -0.49 | 0.46 | 0.63 |
Dividend Per Share | 0.680 | 0.680 | 0.180 | 0.540 | 1.600 | - |
Dividend Growth | 277.78% | 277.78% | -66.70% | -66.22% | 82.95% | - |
Gross Margin | 50.48% | 49.67% | 50.23% | 51.05% | 49.94% | 56.06% |
Operating Margin | 3.51% | 6.55% | 5.17% | 10.24% | 9.88% | 14.67% |
Profit Margin | 3.59% | 5.77% | 4.62% | 10.99% | 9.80% | 14.97% |
Free Cash Flow Margin | 6.13% | 5.91% | 3.53% | -6.37% | 5.61% | 7.26% |
EBITDA | 76.57 | 105.16 | 87.2 | 115.13 | 99.22 | 127.79 |
EBITDA Margin | 9.27% | 11.68% | 10.74% | 14.66% | 14.35% | 18.80% |
D&A For EBITDA | 47.55 | 46.16 | 45.21 | 34.75 | 30.91 | 28.1 |
EBIT | 29.02 | 59 | 41.98 | 80.38 | 68.31 | 99.69 |
EBIT Margin | 3.51% | 6.55% | 5.17% | 10.24% | 9.88% | 14.67% |
Effective Tax Rate | 18.59% | 19.04% | 19.68% | 14.81% | 17.18% | 14.60% |
Revenue as Reported | 451.55 | 900.77 | 812.13 | 785.19 | 691.57 | 679.7 |
Advertising Expenses | - | 158.6 | 99.88 | 69.92 | 44.22 | - |